Morningstar
•
Jul 31, 2026
Alnylam Pharmaceuticals, Inc.: Alnylam Earnings: Shares Tank Amid Reduced Outlook for Key ATTR Franchise
Summary
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
ARWR: Lowering target price to $87.00
Sep 02, 2026
•
ARWR
EXEL: Raising target price to $63.00
Sep 02, 2026
•
EXEL
SRPT: Raising target price to $17.00
Sep 02, 2026
•
SRPT
ACAD: Lowering target price to $30.00
Sep 02, 2026
•
ACAD
NBIX: Raising target price to $172.00
Sep 02, 2026
•
NBIX
